Vyant Bio, Inc. (VYNT) |
|
0.85 -0.18 (-17.48%)
|
02-03 15:16 |
|
Open: |
0.987 |
Pre. Close: |
1.03 |
|
High:
|
0.99 |
Low:
|
0.8123 |
|
Volume:
|
510,842 |
Market Cap:
|
5(M) |
|
|
|
Technical analysis |
as of: 2023-02-03 2:51:22 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 1.44  One year: 1.84 |
| Support: |
Support1: 0.68 Support2: 0.56 |
| Resistance: |
Resistance1: 1.23 Resistance2: 1.58 |
| Pivot: |
0.89 |
| Moving Average: |
MA(5): 0.94 MA(20): 0.93
MA(100): 1.66 MA(250): 3.36 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 60.3 %D(3): 53.4 |
| RSI: |
RSI(14): 44.7 |
| 52-week: |
High: 9.85 Low: 0.66 |
| Average Vol(K): |
3-Month: 426 (K) 10-Days: 120 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ VYNT ] has closed above bottom band by 34.9%. Bollinger Bands are 67.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.04 - 1.05 |
1.05 - 1.05 |
|
Low:
|
0.95 - 0.96 |
0.96 - 0.96 |
|
Close:
|
1.02 - 1.03 |
1.03 - 1.04 |
|
Company Description |
|
Vyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD). Vyant Bio, Inc. has a collaboration agreement to discover drugs for the treatment of Parkinson's Disease. The company is based in Cherry Hill, New Jersey. |
Headline News |
Fri, 03 Feb 2023
Is it Time to Dump Vyant Bio Inc (VYNT) Stock After it Is Down 7.61% in a Week? - InvestorsObserver
Fri, 03 Feb 2023
Small Nebraska startup hopes to challenge Pfizer, Merck in ... - Endpoints News
Fri, 03 Feb 2023
Vyant Bio CEO to Step Down, Successor Named; Cuts Staff as Strategic Review Process Gets Underway - Marketscreener.com
Fri, 03 Feb 2023
VYNT: Withdrawing Valuation - Yahoo Finance
Fri, 03 Feb 2023
Vyant CEO to step down as board plans to reduce workforce ... - Seeking Alpha
Wed, 11 Jan 2023
Where Does Vyant Bio Inc (VYNT) Stock Fall in the Biotechnology Field After It Is Up 36.36% This Week? - InvestorsObserver
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
29 (M) |
|
% Held by Insiders
|
2.354e+007 (%) |
|
% Held by Institutions
|
25 (%) |
|
Shares Short
|
97 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-1.505e+007 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-1 |
|
Return on Assets (ttm)
|
442.3 |
|
Return on Equity (ttm)
|
-21.2 |
|
Qtrly Rev. Growth
|
1.08e+006 |
|
Gross Profit (p.s.)
|
-0.01 |
|
Sales Per Share
|
0.13 |
|
EBITDA (p.s.)
|
-0.39 |
|
Qtrly Earnings Growth
|
-1.2 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-14 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
-0.1 |
|
Price to Book value
|
0 |
|
Price to Sales
|
6.32 |
|
Price to Cash Flow
|
0 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
48820 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2019-10-24 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
